Small Cell Lung Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Condition:   Small Cell Lung Carcinoma Interventions:   Dietary Supplement: Cyclic, 5-day calorie restriction;   Drug: Atezolizumab Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   IFOM, The FIRC Institute of Molecular Oncology;   University of Milan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT
Condition:   Patients With Advanced Solid Tumor (Excluding NSCLC, SCLC, and Mesothelioma) With Results From a Multi-gene Next-generation Sequencing (NGS) Panel (>30 Genes) Interventions:   Other: Minimal documentation;   Other: Extended documentation Sponsor:   AIO-Studien-gGmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials